Record #182613 - GSI Repository

TETRA

Autologous Stem Cell Seeded Tissue Engineered Trachea

Coordinator	TMC PHARMA SERVICES LIMITED ; VIDEREGEN LIMITED ; MANCHESTER UNIVERSITY NHS FOUNDATION TRUST ; University of London - University College London ; UNIVERSITY HOSPITAL OF SOUTH MANCHESTER NHS FOUNDATION TRUST ; Instytut Gruźlicy i Chorób Płuc ; Cell Therapy Catapult ; NHS Blood and Transplant ; EURAM LIMITED ; University College London Hospitals NHS Foundation Trust ; University of Brescia ; MEDIZINISCHE UNIVERSITAET WIEN ; KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN ; University of Manchester
Grant period	2016-01-01 - 2019-12-31
Funding body	European Union
Call number	H2020-PHC-2015-single-stage_RTD
Grant number	681027
Identifier	G:(EU-Grant)681027

Note: CLINICAL PROBLEM AND UNMET NEED There are 11,827 patients with severe structural airway disease in Europe. Even with the current standard of care, when hospitalised this group of patients has a 22% risk of dying. Patients are currently subjected to repeated surgical interventions (stent insertion) which have a high failure rate. Other therapeutic strategies under development include synthetic tracheal scaffolds seeded with patients own stem cells. Preliminary data show that these scaffolds are poorly integrated and are susceptible to infection. TETRA PROJECT Our SME-led project will address the limitations of standard clinical care and competitor products under development and will: - Build on our successful compassionate use experience using autologous stem cell seeded scaffold-tracheal transplants in 48 patients - Follow on from our Phase I 4 patient INSPIRE clinical trial which will improve on the clinical prototype used in compassionate use cases - Conduct a 48 patient Phase II pivotal clinical trial to provide robust, quality data with validated GMP manufacturing processes to support an accelerated route to market for commercial exploitation in this orphan indication - Prepare a dossier for MAA submission BENEFITS Our product, an ATMP, aims to eliminate the need for repeated surgical interventions of high risk and limited efficacy, reduce deaths and improve the quality of life for surviving patients. If treating 20% of the patients with severe structural airway disease, we estimate that in Europe our technology will improve the quality and length of patient lives and result in savings of €517 million per year. We plan to further develop our platform technology to generate other complex tissues/organs such as bowel and liver replacements for clinical applications which will impact the lives of tens of thousands of patient in the EU with bowel and liver diseases.

Recent Publications

There are no publications

Record created 2015-12-04, last modified 2023-02-14

Similar records

Add to personal basket
Export as Author List with IDs BibTeX (UTF-8), EndNote XML, EndNote Text, RIS, MARC, Print MARC, MARCXML, DC,
Request correction
Submit fulltext

GSI Homepage \| GSI Library \| English Deutsch \| guest :: login GSI Repository
Search	Submit	Personalize Your alerts Your baskets Your searches	Help